Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions.

Dehdashti SJ, Abbott J, Nguyen DT, McKew JC, Williamson PR, Zheng W.

Anal Bioanal Chem. 2013 Aug;405(21):6823-9. doi: 10.1007/s00216-013-7134-4. Epub 2013 Jun 30.

2.

A high-throughput screening assay for fungicidal compounds against Cryptococcus neoformans.

Rabjohns JL, Park YD, Dehdashti J, Sun W, Henderson C, Zelazny A, Metallo SJ, Zheng W, Williamson PR.

J Biomol Screen. 2014 Feb;19(2):270-7. doi: 10.1177/1087057113496847. Epub 2013 Jul 29.

3.
4.

In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

Perfect JR, Cox GM, Dodge RK, Schell WA.

Antimicrob Agents Chemother. 1996 Aug;40(8):1910-3.

5.

Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.

Butts A, Koselny K, Chabrier-Roselló Y, Semighini CP, Brown JC, Wang X, Annadurai S, DiDone L, Tabroff J, Childers WE Jr, Abou-Gharbia M, Wellington M, Cardenas ME, Madhani HD, Heitman J, Krysan DJ.

MBio. 2014 Feb 11;5(1):e00765-13. doi: 10.1128/mBio.00765-13.

6.

Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.

Khyriem AB, Sujatha S, Parija SC.

Indian J Pathol Microbiol. 2006 Apr;49(2):307-8.

PMID:
16933750
7.

Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.

Pfaller M, Zhang J, Messer S, Tumberland M, Mbidde E, Jessup C, Ghannoum M.

Diagn Microbiol Infect Dis. 1998 Nov;32(3):191-9.

PMID:
9884835
8.

Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro.

Martinez LR, Casadevall A.

Antimicrob Agents Chemother. 2006 Mar;50(3):1021-33.

9.
10.
11.

Novel cell-based in vitro screen to identify small-molecule inhibitors against intracellular replication of Cryptococcus neoformans in macrophages.

Samantaray S, Correia JN, Garelnabi M, Voelz K, May RC, Hall RA.

Int J Antimicrob Agents. 2016 Jul;48(1):69-77. doi: 10.1016/j.ijantimicag.2016.04.018. Epub 2016 May 26.

12.

Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS.

Rodero L, Córdoba S, Cahn P, Soria M, Lucarini M, Davel G, Kaufman S, Canteros C, Guelfand L.

Med Mycol. 2000 Jun;38(3):201-7.

PMID:
10892987
13.

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.

Klepser ME, Wolfe EJ, Pfaller MA.

J Antimicrob Chemother. 1998 Mar;41(3):397-401.

PMID:
9578168
14.

Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.

Manosuthi W, Sungkanuparph S, Thongyen S, Chumpathat N, Eampokalap B, Thawornwan U, Foongladda S.

J Med Assoc Thai. 2006 Jun;89(6):795-802.

PMID:
16850679
15.

Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Sorrell TC, Patterson TF.

Antimicrob Agents Chemother. 2013 Feb;57(2):745-50. doi: 10.1128/AAC.01624-12. Epub 2012 Nov 19.

16.

Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays.

Treviño-Rangel Rde J, Villanueva-Lozano H, Hernández-Rodríguez P, Martínez-Reséndez MF, García-Juárez J, Rodríguez-Rocha H, González GM.

Med Mycol. 2016 Mar;54(3):280-6. doi: 10.1093/mmy/myv109. Epub 2015 Dec 24.

PMID:
26705833
17.

Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans.

Shen J, Davis LE, Wallace JM, Cai Y, Lawson LD.

Planta Med. 1996 Oct;62(5):415-8.

PMID:
8923805
18.

3-Bromopyruvate: a novel antifungal agent against the human pathogen Cryptococcus neoformans.

Dyląg M, Lis P, Niedźwiecka K, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Biochem Biophys Res Commun. 2013 May 3;434(2):322-7. doi: 10.1016/j.bbrc.2013.02.125. Epub 2013 Mar 26.

PMID:
23541578
19.

Thiazole compounds with activity against Cryptococcus gattii and Cryptococcus neoformans in vitro.

Pereira de Sá N, Lino CI, Fonseca NC, Borelli BM, Ramos JP, Souza-Fagundes EM, Rosa CA, Santos DA, Barbosa de Oliveira R, Johann S.

Eur J Med Chem. 2015 Sep 18;102:233-42. doi: 10.1016/j.ejmech.2015.07.032. Epub 2015 Jul 17.

PMID:
26276437
20.

Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.

Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y.

J Antimicrob Chemother. 2004 Aug;54(2):563-5. Epub 2004 Jul 14.

PMID:
15254027

Supplemental Content

Support Center